Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Tremfya (guselkumab)
Pharma
Tremfya enters crowded ulcerative colitis arena with FDA nod
Tremfya enters the space as J&J’s Stelara, which is approved for both forms of IBD, nears biosimilar competition and IRA-related price concessions.
Zoey Becker
Sep 11, 2024 6:58pm
J&J nixes Tremfya trial in giant cell arteritis
Jun 25, 2024 4:45pm
Subcutaneous version of J&J's Tremfya excels in Crohn's trial
Jun 20, 2024 11:12am
UPDATED: J&J readies Tremfya for IBD showdown with AbbVie, Lilly
May 21, 2024 9:49am
J&J shows psoriasis drug Tremfya works across all skin tones
Oct 20, 2023 10:05am
Intra-Cellular winner of the Fierce Madness Drug Ad Tournament
Mar 22, 2023 8:30am
